IL149097A0 - 4-carboxyamino-2-ethyl-1,2,3,4-thetrahydroquinoline crystal as cetp inhibitor - Google Patents
4-carboxyamino-2-ethyl-1,2,3,4-thetrahydroquinoline crystal as cetp inhibitorInfo
- Publication number
- IL149097A0 IL149097A0 IL14909700A IL14909700A IL149097A0 IL 149097 A0 IL149097 A0 IL 149097A0 IL 14909700 A IL14909700 A IL 14909700A IL 14909700 A IL14909700 A IL 14909700A IL 149097 A0 IL149097 A0 IL 149097A0
- Authority
- IL
- Israel
- Prior art keywords
- thetrahydroquinoline
- carboxyamino
- ethyl
- crystal
- cetp inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16805199P | 1999-11-30 | 1999-11-30 | |
PCT/IB2000/001650 WO2001040190A1 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
IL149097A0 true IL149097A0 (en) | 2002-11-10 |
Family
ID=22609901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14909700A IL149097A0 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-ethyl-1,2,3,4-thetrahydroquinoline crystal as cetp inhibitor |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1246804A1 (en) |
JP (1) | JP2003515592A (en) |
KR (1) | KR20020058057A (en) |
CN (1) | CN1402711A (en) |
AP (1) | AP2002002531A0 (en) |
AU (1) | AU1048801A (en) |
BG (1) | BG106854A (en) |
BR (1) | BR0015836A (en) |
CA (1) | CA2392979A1 (en) |
CO (1) | CO5271716A1 (en) |
EA (1) | EA200200510A1 (en) |
EC (1) | ECSP003792A (en) |
EE (1) | EE200200277A (en) |
GT (1) | GT200000199A (en) |
HU (1) | HUP0203521A2 (en) |
IL (1) | IL149097A0 (en) |
IS (1) | IS6338A (en) |
MA (1) | MA26845A1 (en) |
MX (1) | MXPA02005354A (en) |
NO (1) | NO20022558L (en) |
OA (1) | OA12099A (en) |
PA (1) | PA8506301A1 (en) |
PE (1) | PE20010904A1 (en) |
PL (1) | PL355892A1 (en) |
TN (1) | TNSN00231A1 (en) |
TR (1) | TR200201446T2 (en) |
UY (1) | UY26454A1 (en) |
WO (1) | WO2001040190A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
JP2005500314A (en) * | 2001-06-21 | 2005-01-06 | ファイザー・プロダクツ・インク | Self-emulsifying formulation of cholesterol ester transfer protein inhibitor |
GT200200170A (en) * | 2001-09-28 | 2003-05-23 | PREPARATION OF INHIBITOR OF CETP ANHIDRO | |
EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
EP1469832B2 (en) | 2002-02-01 | 2016-10-26 | Bend Research, Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
CN1309370C (en) * | 2002-02-01 | 2007-04-11 | 辉瑞产品公司 | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
CN1289467C (en) | 2002-08-30 | 2006-12-13 | 日本烟草产业株式会社 | Dibenzylamine compound and medicinal use thereof |
AU2003277285B2 (en) | 2002-10-04 | 2007-12-13 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
DE60331873D1 (en) | 2002-12-20 | 2010-05-06 | Pfizer Prod Inc | Dosage form containing a CETP inhibitor and an HMG-CoA reductase inhibitor |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
EA200501376A1 (en) * | 2003-03-28 | 2006-04-28 | Пфайзер Продактс Инк. | DERIVATIVES OF 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO- and 1,2-DIHYDROCHINOLINES AND 1,2,3,4-TETRAHYDROCHINOXALINE AS AN INHIBITORS CETR FOR THE TREATMENT OF ATHEROSCLEROSIS AND FAT |
CA2532931A1 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
MXPA06003927A (en) | 2003-10-08 | 2008-02-07 | Lilly Co Eli | Compounds and methods for treating dyslipidemia. |
EP1737811B1 (en) * | 2004-04-13 | 2016-08-10 | Merck Sharp & Dohme Corp. | Cetp inhibitors |
KR20070041452A (en) * | 2004-06-24 | 2007-04-18 | 일라이 릴리 앤드 캄파니 | Compounds and methods for treating dyslipidemia |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
WO2006033004A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
WO2006091674A1 (en) | 2005-02-24 | 2006-08-31 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
WO2006098394A1 (en) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Method for inhibiting lipid absorption and lipid absorption inhibitor |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
TW200901959A (en) | 2007-03-09 | 2009-01-16 | Indigene Pharmaceuticals Inc | Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications |
US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
TWI450896B (en) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
EP3174995B1 (en) | 2014-07-30 | 2020-08-19 | F.Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
AU5731098A (en) * | 1997-02-03 | 1998-08-25 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/en unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/en unknown
- 2000-11-14 EA EA200200510A patent/EA200200510A1/en unknown
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 EE EEP200200277A patent/EE200200277A/en unknown
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Application Discontinuation
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/en not_active Application Discontinuation
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/en not_active IP Right Cessation
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/en unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/en not_active Application Discontinuation
- 2000-11-14 IL IL14909700A patent/IL149097A0/en unknown
- 2000-11-14 CN CN00816463A patent/CN1402711A/en active Pending
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/en unknown
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/en unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/en active Pending
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-28 UY UY26454A patent/UY26454A1/en not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/en not_active Application Discontinuation
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/en unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/en unknown
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/en unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/en unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/en unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/en not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001040190A1 (en) | 2001-06-07 |
EE200200277A (en) | 2003-10-15 |
AP2002002531A0 (en) | 2002-06-30 |
OA12099A (en) | 2006-05-04 |
MXPA02005354A (en) | 2002-12-11 |
TR200201446T2 (en) | 2002-11-21 |
UY26454A1 (en) | 2001-07-31 |
AU1048801A (en) | 2001-06-12 |
EP1246804A1 (en) | 2002-10-09 |
NO20022558D0 (en) | 2002-05-29 |
PE20010904A1 (en) | 2001-09-10 |
KR20020058057A (en) | 2002-07-12 |
BR0015836A (en) | 2002-08-06 |
CA2392979A1 (en) | 2001-06-07 |
JP2003515592A (en) | 2003-05-07 |
GT200000199A (en) | 2002-05-23 |
CN1402711A (en) | 2003-03-12 |
CO5271716A1 (en) | 2003-04-30 |
NO20022558L (en) | 2002-05-29 |
HUP0203521A2 (en) | 2003-02-28 |
ECSP003792A (en) | 2002-04-23 |
PL355892A1 (en) | 2004-05-31 |
PA8506301A1 (en) | 2002-08-26 |
TNSN00231A1 (en) | 2002-05-30 |
EA200200510A1 (en) | 2002-10-31 |
IS6338A (en) | 2002-04-12 |
MA26845A1 (en) | 2004-12-20 |
BG106854A (en) | 2002-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL149097A0 (en) | 4-carboxyamino-2-ethyl-1,2,3,4-thetrahydroquinoline crystal as cetp inhibitor | |
MXPA01013406A (en) | Vla-4 inhibitor compounds. | |
EP1140083A4 (en) | Novel compounds | |
GB9902084D0 (en) | Novel compounds | |
IL149424A0 (en) | 14,15-beta-methylene substituted androgens | |
EG24063A (en) | Novel compounds | |
GB9901256D0 (en) | Novel compounds | |
GB9902070D0 (en) | Novel compounds | |
ZA200109203B (en) | VLA-4 inhibitor compounds. | |
CA88270S (en) | Sunglasses | |
CA88264S (en) | Sunglasses | |
CA88265S (en) | Sunglasses | |
GB9912319D0 (en) | Novel compounnds | |
GB9903265D0 (en) | Novel use | |
GB9906061D0 (en) | Novel use | |
GB9915469D0 (en) | Novel use | |
HK1062445A1 (en) | B-secretase inhibitor. | |
AU137566S (en) | Sunglasses | |
AU141770S (en) | Sunglasses | |
AU141771S (en) | Sunglasses | |
AU141772S (en) | Sunglasses | |
AU141768S (en) | Sunglasses | |
AU141767S (en) | Sunglasses | |
AU141769S (en) | Sunglasses | |
GB9902077D0 (en) | Novel compounds |